0.1826
1.67%
-0.0031
Pre-market:
.1822
-0.0004
-0.22%
Matinas Biopharma Holdings Inc stock is currently priced at $0.1826, with a 24-hour trading volume of 1.53M.
It has seen a -1.67% decreased in the last 24 hours and a -50.62% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1867 pivot point. If it approaches the $0.179 support level, significant changes may occur.
Previous Close:
$0.1857
Open:
$0.1848
24h Volume:
1.53M
Market Cap:
$45.80M
Revenue:
-
Net Income/Loss:
$-22.94M
P/E Ratio:
-1.66
EPS:
-0.11
Net Cash Flow:
$-15.50M
1W Performance:
+0.44%
1M Performance:
-50.62%
6M Performance:
-12.55%
1Y Performance:
-69.59%
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-26-20 | Resumed | Piper Sandler | Overweight |
Jan-27-20 | Initiated | Piper Sandler | Overweight |
Jan-24-20 | Initiated | SunTrust | Buy |
Jan-23-20 | Initiated | SunTrust | Buy |
Jan-09-20 | Initiated | Aegis Capital | Buy |
Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Matinas BioPharma Prices $10 Million Registered Direct Offering
GlobeNewswire Inc.
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
GlobeNewswire Inc.
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
GlobeNewswire Inc.
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
GlobeNewswire Inc.
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
GlobeNewswire Inc.
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
GlobeNewswire Inc.
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Matinas Biopharma Holdings Inc (MTNB) Net Income 2024
MTNB net income (TTM) was -$22.94 million for the quarter ending December 31, 2023, a -9.26% decrease year-over-year.
Matinas Biopharma Holdings Inc (MTNB) Cash Flow 2024
MTNB recorded a free cash flow (TTM) of -$15.50 million for the quarter ending December 31, 2023, a +22.71% increase year-over-year.
Matinas Biopharma Holdings Inc (MTNB) Earnings per Share 2024
MTNB earnings per share (TTM) was -$0.12 for the quarter ending December 31, 2023, a -9.09% decline year-over-year.
About Matinas Biopharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
Cap:
|
Volume (24h):